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Background  
 
Transmembrane and soluble TNF  
Tumor necrosis factor (TNF) is the prototype molecule of the TNF superfamily 
(TNFSF), exerting a broad spectrum of activities through its membrane bound or 
soluble form. TNF is a pleiotropic cytokine as it is able to induce differentiation, 
gene-expression, apoptosis or necrosis depending on the type and actual state of 
the responding cells. TNF is mainly expressed by immune cells but also by other 
cell types. The 26 kDa membrane bound TNF (tmTNF) is synthesized as a 
monomer type II polypeptide and assembles into a functional trimer. Mature, 
soluble TNF is cleaved from tmTNF by TACE. The synthesis of TNF can be 
induced by many different stimuli including interferons, cytokines, tumor cells, 
irradiation and hypoxia. Factors from bacteria, viruses, and parasites can also 
stimulate the production of TNF.  
TNF mediates biological activities through type 1 and 2 TNF receptors (TNFR1 
and TNFR2), which are expressed as pre-assembled trimers on the cell surface. 
While TNFR1 is expressed in all nucleated cells, TNFR2 is mainly expressed in 
immune cells, endothelial cells and neurons. Binding of sTNF to its receptors 
triggers a series of intracellular events that result in the activation of transcription 
factors, such as NF-κB and c-Jun. TNF-activated complex signaling pathways 
mediate diverse biological processes, including cell growth, cell death, 
development, inflammatory or stress responses. Whether stimulation of a cell 
leads to activation or apoptosis, depends on a complex interplay between the 
metabolic status and microenvironment of the given cell type. Systemic activities 
of TNF are associated with the secreted soluble form. Level of circulating TNF in 
healthy individuals is nearly undetectable, but increases dramatically in 
pathological cases.  
TNF is a key mediator in the local inflammatory immune response as it acts as an 
acute phase protein which initiates a cascade of cytokines and increases vascular 
permeability, recruiting in turn macrophages and neutrophils to the site of 
infection. Up-regulation of TNF is known to play a critical role in pathogenic 
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disorders like rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, 
septic shock and inflammatory bowel disease.  
 
Transmembrane TNF as a ligand  
Similar to soluble TNF, tmTNF exists as a homotrimer of uncleaved monomers, 
with a molecular weight of 26 kDa. Transmembrane TNF also binds to both 
subtypes of TNF receptors on target cells, however biological activities are 
supposed to be mediated mainly through TNFR2. Leading to cell death or 
activation of the target cells, expression of tmTNF contributes to physiological 
and pathological responses. Cytotoxic activities of tmTNF have been reported for 
various tumor cells. Importance of tmTNF in inhibition of intracellular pathogens 
has been also reported. Furthermore, tmTNF has been shown to initiate T cell and 
macrophage migration as well as granuloma formation. Direct cell-to-cell contacts 
through tmTNF trigger activation processes in endothelial cells, B cells, T cells, 
monocytes and NK cells. 
 
Transmembrane TNF as a receptor  
When TNF superfamily ligands and their cognate receptors interact, signaling 
pathways can be activated in both ligand and receptor bearing cells, leading to 
activation, differentiation or apoptosis. This bidirectional communication has been 
reported for a number of TNF superfamily members and considered as a fine-
tuning mechanism during the immune response. We and others reported receptor-
like properties of the tmTNF. Soluble ectodomain of receptor molecule (e.g. 
Etanercept) or anti-TNF antibodies (e.g. Infliximab, Adalimumab) can also elicit 
reverse signaling in tmTNF expressing cells  Therapeutic application of these 
agents in chronic inflammatory diseases such as rheumatoid arthritis and Crohn´s 
disease revealed effects of TNF reverse signaling on different immune cells 
mostly depending on the cell type, including apoptosis or activation. Moreover, 
TNF reverse signaling has been implicated in undesirable side-effects of anti-TNF 
therapies, where secondary infections were observed.  
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Despite the apparent clinical relevance the molecular basis of TNF reverse 
signaling is largely unknown. The first reports revealed protein kinase C and 
MAPK/ERK to be involved in TNF reverse signaling. Interaction of tmTNF with 
its soluble receptor triggers rapid dephosphorylation of tmTNF and concomitant 
Ca2+ signaling. The MAPK pathway and caspases have been implicated in 
downstream signaling events, whereas other possible participating molecules 
remained elusive.  
 
Casein kinase 2-interacting protein-1 (CKIP-1) is a multifunctional protein  
Identifying signaling molecules recruited to the mTNF molecule and investigating 
their role may help to unravel molecular details of TNF reverse signaling. A novel 
protein that interacts with the intracellular domain of mTNF has been identified 
(hTIP, human TNF intracellular domain interacting protein) and proved to be 
identical to human casein kinase 2-interacting protein-1 (CKIP-1). CKIP-1 has 
been found to interact with a series of proteins involved in cellular functions like 
differentiation, cell motility and cell death.  
 
2 Aim of the study  
Since CKIP-1 has been identified as an interacting partner of the pro-
inflammatory tmTNF, we hypothesized that it might have a role in immunity as 
well. We aimed at elucidating possible functions of the novel protein CKIP-1 in 
innate immunity.  
Our specific aims were:  
I) to investigate the involvement of CKIP- 1 in the pro-inflammatory response of 
human and mouse mononuclear cells;  
II) to reveal the role of CKIP-1 in TNF reverse signaling in human model cell 
lines.  
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Materials and Methods  
 
Cell culture  
HEK293 cells (ATCC) were grown in a (1:1) mixture of Dulbecco's modified 
Eagle's medium and Ham's F-12 medium supplemented with 10 % low endotoxin 
FCS. THP-1 (ATCC) cells were maintained in OptiMEM with 2 % FCS.  
 
Expression vectors  
The human CKIP-1 coding sequence was kindly provided by Dr. Chie Kohchi 
(Hiroshima University, Japan) and subcloned into pBS-SK+ and into vectors 
pcDNA3, pEGFPC1, pECFPC1 and p3xFlag-Myc-CMV-26. The 252 bp N 
terminal fragment of tmTNF (TNFNterm) was fused to GST, EYFP or mCherry. 
In promoter activation experiments the luciferase gene was controlled by the 
TNF-alpha promoter or a promoter sequence containing 5x NF-κB binding sites.  
 
Transient transfections and reporter gene assays  
THP-1 and HEK293 cells were transiently transfected by Lipofectamine-2000, or 
Jet PEI or by Amaxa Nucleofector kit following the manufacturer's protocols. To 
analyze the effect of CKIP-1 on the transcriptional activity of c-Jun the 
PathDetectTM Trans-Reporting System was used (Stratagene). 
 
Protein expression, purification and GST-pull down assay  
GST fusion proteins were purified from E. coli BL21 (DE3) lysates using 
glutathione-Sepharose beads. CKIP-1 was transcribed and translated in vitro using 
the TNT coupled reticulocyte system (Promega) then incubated with fusion 
protein or GST immobilized on glutathione-Sepharose beads. 35S-labeled proteins 
were detected by SDS PAGE followed by autoradiography.  
 
Immunoprecipitations and immunoblotting 
Immunoprecipitations were performed using the Pierce direct magnetic IP kit 
(Thermo Scientific) according to the manufacturer’s protocol using monoclonal 
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anti-Flag M2 (Sigma) or anti-RFP (Abcam) antibodies. Proteins were detected by 
Western blotting using anti-CKIP-1 (Santa Cruz) or anti-Flag M2 (Sigma) 
antibody and the appropriate secondary antibody conjugated to HRP (Sigma).  
 
Expression Profile Verification  
Reactions were carried out in ABsolute QPCR SYBR Green mix (ABGene) 
according to the manufacturer's instructions on a RotorGene 3000 instrument 
(Corbett Research). Primer sequences for hCKIP-1 were: 
CCACTCGAGACAGGGCAAAA and AGCCATTAGGTGTCCCCTTGT.  
 
Flow cytometry  
For apoptosis measurements, cells were labeled with Annexin V-Alexa647 
(Invitrogen) following the manufacturer´s instructions. For surface staining 
measurements, transfected cells were stained with Infliximab-A647, anti-human 
B7/CD86-APC, anti-human DC-SIGN-APC or the appropriate isotype controls. 
Samples were analyzed by flow cytometry (BD FACSAriaTM), where cells with 
damaged membranes were gated by PI exclusion.  
 
Ca2+ measurements  
Cells were loaded with 5 µM Indo 1-AM (Invitrogen). In situ treated live cells 
were monitored by fluorescence microscopy. Ratio of fluorescence emission at 
405 nm (Ca2+-bound dye) and at 485 nm (Ca2+-free dye) was calculated for 
individual cells with the software Matlab®.  
 
Fluorescence microscopy  
Cells were analyzed by a custom designed instrument for large area fluorescence 
imaging (CytoScout®) based on an Axiovert 200 microscope (Zeiss). Images were 
analyzed by the V++ software. For co-localization analysis fluorescence images 
were recorded with an Olympus FV10i confocal microscope. The Mander’s 
overlap coefficients were calculated using the JACoP plugin for the ImageJ 
software.  
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Results  
 
CKIP-1 is involved in the inflammatory response of THP-1 cells  
The effect of LPS on the transcriptional activity of ckip-1 was followed in human 
THP-1 monocytes by qRT-PCR method. Level of CKIP-1 mRNA was 
significantly elevated in cells exposed to LPS and a similar upregulation was 
found in protein levels when followed by Western blot analysis. Furthermore, 
CKIP-1 expression was found to facilitate the classical activation process as 
reflected in the significant increase in CD86 surface expression.  
 
CKIP-1 transactivates the TNF promoter in cooperation with-Jun  
Increased levels of CKIP-1 protein had practically no influence on the basal 
activity of the NF-κB transcription factors in HEK293 cells. In contrast, in cells 
transiently co-expressing c-Jun and CKIP-1, a remarkable activation of the TNF 
promoter was observed.  
 
TNF reverse signaling induces Ca2+ oscillations in THP-1 cells  
We used Infliximab, a therapeutic TNF antibody to elicit reverse signaling in 
THP-1 cells that are known to express tmTNF on the cell surface. Treatment with 
the F(ab)2 fragment of Infliximab triggered THP-1 cells to specifically respond 
with Ca2+ signaling.  
 
TNF reverse signaling leads to relocalization of CKIP-1 in THP-1 cells  
When fusion protein CKIP-1-ECFP was expressed in THP-1 cells and visualized 
by confocal microscopy, in resting THP-1 cells CKIP-1 was found predominantly 
at the plasma membrane and also at intracellular regions. In contrast to treatments 
with LPS or hIgG, Infliximab treatment resulted in a remarkable additional 
translocation of CKIP-1 from the plasma membrane to intracellular regions. 
Similarly, a considerable relocalization of CKIP-1 from the plasma membrane to 
intracellular regions was observed in HEK293 model cells upon co-expression of 
TNFNterm, a short N terminal peptide of tmTNF. Similarly to Infliximab-treated 
 8 
THP-1 cells, a considerable relocalization of CKIP-1 from the plasma membrane 
to intracellular regions was observed upon TNFNterm co-expression in HEK293 
model cells.  
 
CKIP-1 interacts with the N terminal fragment of tmTNF  
CKIP-1 has been identified as an interacting partner of the N terminal intracellular 
domain of the pro-inflammatory tmTNF in a yeast two hybrid screen, pointing to 
a possible interaction of these two proteins. Co-localization analysis revealed that 
a significant fraction of TNFNterm positive pixels overlap with those of positive 
for CKIP-1 in HEK293 cells. The interaction of CKIP-1 and TNFNterm was 
corroborated by co-immunoprecipitation and by in vitro pull down assays, as well.  
 
TNF reverse signaling reduces CKIP-1 mediated activation  
Since reverse signaling affected the subcellular localization of CKIP-1 we tested 
whether it influences the CKIP-1 mediated activation processes. Remarkably, the 
CKIP-1 mediated increase in CD86 surface expression was significantly reduced 
upon Infliximab treatment. Similarly, overexpression of TNFNterm reduced the 
co-operative effect of CKIP-1 and c-Jun on TNF promoter activation.  
 
Expression of CKIP-1 prevents cells from TNFNterm/ TNF revese signaling 
induced apoptosis  
In imaging experiments we observed morphological changes and a decreased 
proliferation rate of HEK293 cells expressing TNFNterm, while changes appeared 
to be counteracted in cells co-expressing both TNFNterm and CKIP-1. Indeed, co-
expression of CKIP-1 almost completely prevented HEK293 cells from the 
apoptotic effect of TNFNterm, as measured by flow cytometry. In accordance, 
overexpression of CKIP-1 prevented THP-1cells from Infliximab-induced 
apoptosis. In contrast, CKIP-1 did not appear to interfere with apoptosis induced 
by etoposide.  
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Discussion  
Receptor-like properties of the transmembrane form of the pro-inflammatory 
cytokine TNF have been reported by several laboratories. Although TNF reverse 
signaling has been emerging as an important phenomenon in the immune 
response, its molecular basis remains elusive. Here we examined the role of 
CKIP-1, an interacting partner of the intracellular domain of tmTNF in 
inflammation and TNF reverse signaling. CKIP-1 exhibits diverse functions in 
different cell types such as recruiting proteins to the plasma membrane mediating 
regulation of the actin cytoskeleton, repressing cell survival signaling and 
affecting cell differentiation. Although CKIP-1 has been proposed to control 
cytokine signaling its function in immunity is still unclear. In our model cells 
CKIP-1 exerted a positive regulatory role in the activation process of monocytes. 
CKIP-1 has a fairly complex domain structure with several potential sites for post-
translational modifications, indicating that modifications and interactions of the 
protein might alter its localization and activity. Upon treatment with Infliximab, a 
therapeutically used anti-TNF agent, a massive translocation of CKIP-1 from the 
plasma membrane to intracellular compartments was observed in model cells. 
Interestingly, in parallel with the relocalization of CKIP-1, TNF reverse signaling 
or expression of TNFNterm antagonized the pro-inflammatory effects of CKIP-1. 
Therefore, TNF reverse signaling appeared to have a negative regulatory role in 
inflammation, which is supported by the fact that reverse signaling has been 
shown to induce a temporary LPS resistance in monocytic cells.  
TNF reverse signaling has been shown to activate both proapoptotic and 
antiapoptotic signaling pathways, where fate of the cell depends on the degree of 
differentiation and crosstalk with other signaling pathways. Nevertheless, critical 
signaling molecules determining the fate of the cell upon TNF reverse signaling 
have not been revealed. In our experiments Infliximab treatment induced 
apoptosis in THP-1 cells and CKIP-1 appeared to be a critical factor determining 
the fate of monocytes interacting with anti-TNF agents. Surprisingly, CKIP-1 
could not only prevent THP-1 cells from TNF reverse signaling induced apoptosis 
but increased the survival of the CKIP-1 expressing cells upon Infliximab 
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treatment. Interestingly enough, we showed earlier that the NLS containing 
TNFNterm could accumulate in the nucleus and regulate the transcription of 
cytokines. A similar unusual phenomenon is known for other TNFSF members, 
where upon ligand binding the cleaved intracellular domain of the transmembrane 
molecule translocates into the nucleus and acts as a transcriptional co-activator. 
The apparent correlation between the relocalization of CKIP-1 and TNFNterm, as 
well as the specific interference of CKIP-1 with TNF reverse signaling indicates 
that CKIP-1 and TNFNterm may act through the same signaling complex. This 
idea is consistent with the findings of yeast two hybride, in vitro pull down, co-
immunoprecipitation and co-localization experiments, and further supported by 
the proposed scaffold nature of CKIP-1 as well as the mutual influence on cellular 
activities of CKIP-1 and TNF reverse signaling shown in this work.  
Our data suggest that expression level of CKIP-1 could regulate the response of 
tmTNF expressing immune cells upon TNF reverse signaling. Therefore, CKIP-1 
may be a promising target during local or systemic anti-TNF therapies. We 
propose that further studies on CKIP-1 functions in immunity may contribute to 
more controlled therapeutic approaches. 
Highlights of the study  
1. CKIP-1 expression is elevated upon LPS challenge in human monocyte model 
cells  
2. Excess CKIP-1 results in activation of monocyte model cells.  
3. TNF reverse signaling triggers translocation of CKIP-1, while CKIP-1-
mediated activation is decreased.  
4. CKIP-1 expression counteracts TNF reverse signaling induced apoptosis.  
5. CKIP-1 is proposed as a candidate for regulating the fate of tmTNF expressing 
cells upon TNF reverse signaling.  
 11 
Publications related to the thesis 
 
Juhász K., Zvara Á., Lipp A.M., Nimmervoll B., Sonnleitner A., Balogi Z., Duda 
E. (2013) Casein kinase 2-interacting protein-1, an inflammatory signaling 
molecule interferes with TNF reverse signaling in human model cells. Immunol 
Lett (in press)  
 
Juhász K., Buzás. K., Duda E. (2013) Importance of reverse signaling of the TNF 
superfamily in immune regulation. Expert Rev Clin Immunol 9(4) (in press)  
 
 
Publications not related to the thesis 
Juhász K., Thuenauer R., Spachinger A., Duda E., Horváth I., Vígh L., 
Sonnleitner A., Balogi Z. (2013) Lysosomal rerouting of Hsp70 trafficking as a 
potential immune activating tool for targeting melanoma. Curr Pharm Des; 
19(3):430-40.  
Thuenauer R., Juhász K., Mayr R., Frühwirth T., Lipp A.M., Balogi Z., 
Sonnleitner A. (2011) A PDMS-based biochip with integrated sub-micrometre 
position control for TIRF microscopy of the apical cell membrane. Lab Chip; Sep 
21;11(18):3064-71.  
Réthy B., Hohmann J., Minorics R., Varga A., Ocsovszki I., Molnár J., Juhász 
K., Falkay G., Zupkó I. (2008) Antitumour properties of acridone alkaloids on a 
murine lymphoma cell line. Anticancer Res; Sep-Oct;28(5A):2737-43.  
Balogi Z., Cheregi O., Giese K.C., Juhász K., Vierling E., Vass I., Vígh L., 
Horváth I. (2008) A mutant small heat shock protein with increased thylakoid 
association provides an elevated resistance against UV-B damage in 
synechocystis 6803. J Biol Chem; Aug 22;283(34):22983-91.  
Nagy Z.B., Kelemen J.Z., Fehér L.Z., Zvara A., Juhász K., Puskás L.G. (2005) 
Real-time polymerase chain reaction-based exponential sample amplification for 
microarray gene expression profiling. Anal Biochem. Feb 1;337(1):76-83.  
 
